EuCorVac-19

EuCorVac-19

EuCorVac-19

BUFFALO, NY, February 06, 2022 (GLOBE NEWSWIRE) — POP Biotechnology (ORGANIC POP), a biopharmaceutical startup, announces approval of the Phase 3 clinical study plan for EuCorVac-19, a COVID-19 vaccine candidate developed by South Korean partner EuBiologics (KOSDAQ: 206650, CEO, Dr. Baik YoungOk, M Seukkeun Choi) from the Ministry of Food and Drug Safety of South Korea. EuCorVac-19 is a protein-based vaccine composed of Eubiologics’ protein antigen, EulMT, licensed from the Korea Institute of Science and Technology and the spontaneous antigen particle of nanoliposome (BREAK) POP BIO technology. “This phase III trial is a monumental step forward for our technology. Achieving this critical milestone not only provides validation to resolve this unprecedented global crisis, but also provides invaluable support for the development of our platform, further enabling the creation of new vaccines with enormous potential to alleviate suffering worldwide. says POP BIO President and Co-Founder Jonathan Smyth.

ORGANIC POP Spontaneous particles of nanoliposome antigens (SNAPs) enables rapid development and manufacturing of highly immunogenic particle-based vaccines and immunotherapies directed against infectious diseases and cancer using a cobalt-modified variant of PoP technology (CoPoP). SNAP technology enables stable particle formation and presentation in liposomes of protein and peptide antigens, resulting in substantial improvements in immune responses. According to Dr. Jonathan Lovell, inventor of the technology and co-founder of POP BIO, “SNAP is a vaccine platform technology that could be applicable to any vaccine-related indication, for chronic and infectious diseases. human for COVID-19 the vaccine will reduce the risks of the technology for many other indications.”

Eubiologics will be able to begin phase III controlled trials for 4,000 healthy participants in the Philippines, Bangladesh and other countries based on a standard comparison clinical trial guideline. Eubiologics will work closely with international research organizations to accelerate recruitment in countries with low vaccination rates as well as analysis of trial results to accelerate regulatory approval and commercialization of EuCorVac-19. EuCorVac-19 has already proven its safety and efficacy in phase I/II clinical trials, the results of which were announced in December 2021. Eubiologics plans to accelerate the development of an Omicron variant vaccine based on the same platform as used for EuCorVac-19. A company official said, “The company has already entered into memorandums of understanding on the supply of products with partners in the Philippines and Saudi Arabia, and many Asian, CIS and Latin American partners have come forward. great interest in EuCorVac-19. After the product is launched, the company will target overseas markets which have a high population and middle income depending on the product’s safety, efficacy and logistical convenience. »

ORGANIC POP is a private biotechnology company focused on the research and development of new treatments and vaccines using their proprietary liposome porphyrin-phospholipid (PoP) technologies. PoP technology is licensed exclusively from SUNY-RF.

Eubiologics is a South Korean biotechnology company that received funding for the EuCorVac-19 phase I/II trial from the New Drug Development Committee of the Korean Ministry of Health and Welfare and recently submitted the application for phase III trial for additional financial assistance. Eubiologics has two main animal-based bioreactors (1000 L) to produce recombinant protein antigens to Chuncheon Plant 1 and EcML which is an adjuvant to Chuncheon Plant 2. The total capacity of COVID-19 vaccine is 100-200 million doses per year. The EuCorVac-19 vaccine uses the same type of cell line, which is intended for antibody treatment, so if the company uses these facilities, its manufacturing capacity can be further expanded.

For more information contact: [email protected]

Related images

Image 1: EuCorVac-19

This content was published via the newswire.com press release distribution service.

Attachment